AVAglio concluded the addition of BEV significantly improved PFS, with better preservation of QoL but the final OS analysis did not reach statistical significance.[ 69 ] The two trials, RTOG 0825 and AVAglio, were similar in design, patient characteristics, and the primary end points of PFS and OS.[ 94 ] Nevertheless, some methodological differences were oberved: In the RTOG 0825 study, patients who had undergone a biopsy were excluded, whereas biopsy patients could be randomized in the AVAglio trial; stratification factors differed between the two studies (MGMT status and molecular profile in the RTOG study vs.
2
—
—
The sentences
Cilengitide combination treatment showed a nonsignificant trend only in increasing OS in GB patients with unmethylated MGMT promoter, a finding that replicated the failure of Cilengitide to improve OS seen in the CENTRIC trial.[ 202 ] CENTRIC and CORE trials determined that there is no survival advantage for adding anti-αvβ3-αvβ5-integrin therapy (Cilengitide) to SOC for patients with newly diagnosed GB.